KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biogen (BIIB) EPS (Weighted Average and Diluted) (2016 - 2026)

Biogen has reported EPS (Weighted Average and Diluted) over the past 18 years, most recently at $2.15 for Q1 2026.

  • For Q1 2026, EPS (Weighted Average and Diluted) rose 31.1% year-over-year to $2.15; the TTM value through Mar 2026 reached $9.3, down 8.19%, while the annual FY2025 figure was $8.79, 21.38% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q1 2026 was $2.15 at Biogen, up from -$0.35 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $7.84 in Q3 2022 and troughed at -$0.47 in Q3 2023.
  • A 5-year average of $3.0 and a median of $2.67 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 665.96% in 2024 and later crashed 119.13% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at $3.8 in 2022, then tumbled by 55.0% to $1.71 in 2023, then grew by 7.02% to $1.83 in 2024, then crashed by 119.13% to -$0.35 in 2025, then surged by 714.29% to $2.15 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for BIIB at $2.15 in Q1 2026, -$0.35 in Q4 2025, and $3.17 in Q3 2025.